Bristol-Myers’ Opdivo and Yervoy Combination Couldn’t Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo

Shots:

• The P-III Checkmate-451 involves assessing Opdivo (nivolumab, 1mg/kg) + Yervoy (ipilimumab,3 mg/kg) vs PBO as a maintenance therapy in patients with extensive-stage small cell lung cancer (SCLC)
• The study demonstrated unmet 1EPs & 2EPs as OS with no new safety signals observed in patients
• Opdivo is an PD-1 inhibitor indicated to treat multiple cancer and is currently approved in 65 countries including the US, EU Japan & China

Click here to read full press release/ article | Ref: Bristol-Myers | Image: Irishamerica